Nonrelapse Mortality After CAR-T Therapy Remains High
“Nonrelapse mortality needs to be defined prospectively for all ongoing CAR-T studies,” said the researchers.
“Nonrelapse mortality needs to be defined prospectively for all ongoing CAR-T studies,” said the researchers.
A deep dive into how CAR-T cells evolved in 2 patients with chronic lymphocytic leukemia who have had the longest complete remissions to date.
An anti-BCMA CAR-T therapy appeared to be safe and effective for patients with relapsed or refractory multiple myeloma.
A second-generation anti-CD19 chimeric antigen receptor T-cell therapy showed clinical benefit and low toxicity in a phase 1 trial for B-cell lymphoma.
New possible mechanisms of resistance to CD19 CAR-T were put forth for B-cell acute lymphoblastic leukemia.
Bruce Levine, PhD, explains why targeting multiple antigens simultaneously may be the most promising approach for adoptive cell therapies such as CAR-T.
Interestingly, a number of patients ultimately achieving a sustained complete response initially experienced a partial response to this CAR T-cell therapy.
How one facility ensures compliance with a complex treatment protocol.
This first-in-human trial will enroll up to 24 patients.
Future studies will look at combining the therapy with anti-PD1 blockade.